Navigation Links
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
Date:8/29/2014

previous glioblastoma clinical trials conducted by the National Cancer Institutes in the United States. The Company believes that such higher doses may enhance the potential of VAL-083 to impact a patent's tumor and improve patient outcomes. Ultimately, DelMar believes advancing to higher doses will increase the chance of success in achieving the longer-term goal to commercialize VAL-083 as a new chemotherapy for glioblastoma patients who have failed, or are unlikely to respond, to currently available treatments.
  • DelMar presented new non-clinical research supporting the potential utility of VAL-083 in the treatment of non-small cell lung cancer at AACR in April.
  • DelMar received an additional CDN $194,000 nonrefundable funding contribution from that National Research Council of Canada (NRC). Four non-dilutive funding contributions to date from NRC total CDN $327,000 and will be used to support continued non-clinical research aimed at providing competitive differentiation for VAL-083 as a new medicine in the treatment of glioblastoma and other cancers, including non-small cell lung cancer.
  • DelMar received gross proceeds of $2,373,937 from the exercise of warrants at $0.65 per warrant that closed on June 6 and an additional $495,448 in gross proceeds from exercise of these warrants under the tender offer which closed on August 8. The exercise of warrants through a private transaction with certain warrant holders and subsequent tender offer has provided the Company with additional non-dilutive capital, which the Company believes will be sufficient to fund current operations through at least the end of December 2015. 
  • Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals stated, "We are pleased with the overall progress made during the past year in research and development activities. The warrant tender offer and change in our fiscal year end are part of our ove
    '/>"/>

    SOURCE DelMar Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
    2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
    3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
    4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
    5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
    6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
    7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
    8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
    9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
    10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
    11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe ... Italy , UK, Spain ) Summary GBI ... Europe ( Germany , France , ... analysis of the transcatheter heart valves market in Europe . ... period and key company share data by revenue in 2013 for the following ...
    (Date:9/23/2014)... -- Report Details Where is the prostate cancer ... potential revenues to 2024, assessing data, trends, opportunities and ... charts, and graphs. Our new study lets you assess ... market, showing their prospects to 2024. Discover the most ... prospects. Our new study lets you assess forecasted sales ...
    (Date:9/23/2014)... , Sept. 23, 2014  SI-BONE, Inc., a medical ... Implant System, ® a minimally invasive surgical (MIS) ... today announced that the U.S. Patent and Trademark Office ... and methods for the fixation and fusion of bone.  ... implant with a tapered distal end that may be placed from one ...
    Breaking Medicine Technology:Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 3The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 4The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 5SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3
    ... a biotechnology company that develops targeted therapies for oncology ... results from studies of TRC105 and TRC102 in patients ... Society of Clinical Oncology annual meeting this May 28th ... pathways with the potential for broad application to a ...
    ... Confirm Tapentadol Efficacy and Tolerability for Acute Pain PatientsRARITAN, ... to 30 percent of all people who have surgery ... The use of opioid pain medicines during and after ... side effects. Nausea and vomiting are uncomfortable and bothersome ...
    Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 3New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 5New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 6New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 7New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 8
    (Date:9/23/2014)... Oakland, California (PRWEB) September 23, 2014 ... knows everything about cultivating, growing and harvesting marijuana. He ... innovators in the field and he’ll be leading a ... from 10:00 am to 5:00 pm at Oaksterdam ... cover cultivation law, botany and nomenclature, harvesting and manicuring, ...
    (Date:9/23/2014)... ZEPHYRHILLS, FL (PRWEB) September 23, 2014 ... opening of the newly renovated Women’s Health Center ... square feet of space, the specially designed center ... women in East Pasco County. The Women’s Health ... and pelvic floor health, labor and delivery through ...
    (Date:9/23/2014)... TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS ... WHAT: , The National Institutes of Health is convening ... scientific evidence on the long-term effectiveness and potential risks ... among the nation,s top experts in the field of ... well as key NIH scientists who focus on pain ...
    (Date:9/23/2014)... September 24, 2014 From first-hand experience, ... (PTSD) – and how it can be treated. , ... in Iraq in 2006. His platoon sustained multiple attacks ... he was diagnosed with combat-related PTSD and honorably discharged ... angry, and I had distanced myself from my friends ...
    (Date:9/23/2014)... Dr. Connie Casad has announced that she will be ... at 12200 Park Central Drive, Suite 200, Dallas, Texas 75251 ... Cities Aesthetics, Optimal Health and Wellness, her gynecology practice and ... Casad said, “The patients’ comfort and satisfaction are our primary ... to always feel like their needs are valued and recognized ...
    Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2
    ... ... Geriatrics Association shows a new virtual reality device, the GaitAid, can help stroke patients learn to ... Haifa, Israel (PRWEB) February ... stroke each year. It is one of the leading causes of adult disability in the U.S. ...
    ... ATLANTA--A new study has found that many male cancer ... radiation therapy have an impaired quality of life and ... , a peer-reviewed journal of the American Cancer Society, ... testosterone deficiency may benefit from testosterone replacement therapy. ...
    ... , ... ... ... ...
    ... ... opens it newest location in beautiful Olde Towne Gaithersburg Maryland. Funeral Directors assist ... and multicultural community. , ... Gaithersburg, MD (PRWEB) February 21, 2010 -- A new, affordable option in funeral ...
    ... three million children have been born as a result of ... tube baby" in 1978. While the majority of these ... at greater risk of certain kinds of birth defects and ... and type 2 diabetes later in life. Carmen Sapienza, ...
    ... ... Lauderdale, now offers both the Cisco CCNA Security (prerequisite) and Cisco CCSP Certification Courses ... ... as a prerequisite course. These courses may now be taken at the warm ...
    Cached Medicine News:Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 3Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 4Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 5Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 2Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 3Health News:Cisco CCSP Now Requires CCNA Security as Prerequisite 2Health News:Cisco CCSP Now Requires CCNA Security as Prerequisite 3
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: